Funding comes from other agencies besides the DoD
CRS 21- Congressional Research Service (“Domestic Funding for COVID-19 Vaccines: An Overview,” CRS, 3-29-21, Accessed Online at https://crsreports.congress.gov/product/pdf/IN/IN11556, Accessed Online on 7-4-22)
COVID-19 vaccine research and development (R&D), regulation, manufacture, and purchase have been largely supported by a collaboration among several federal agencies, including the National Institutes of Health (NIH), the Biomedical Advanced Research and Development Authority (BARDA), FDA, DOD, and others (formerly OWS). Six vaccines were chosen for coordinated federal support under OWS. Some vaccine R&D has been supported by NIH, BARDA, and DOD separately from the OWS efforts. For R&D, funding has been provided to accounts at NIH, DOD, and the Public Health and Social Services Emergency Fund (PHSSEF; parent account for BARDA) for COVID-19 related R&D, including vaccine R&D. In addition, over $50 billion in PHSSEF funding has been made available until September 24, 2024 for a broad set of medical countermeasures and surge capacity purposes, including for the development, manufacture, and purchase of vaccines and related supplies. Separately, FDA has received broad supplemental appropriations for its regulatory and other activities. ARPA (P.L. 117-2) further provides appropriations that can be used for activities under this heading (all ARPA funds are mandatory appropriations): Section 2303 provides $6.05 billion to HHS, available until expended, for research, development, manufacturing, production, and the purchase of vaccines, therapeutics, and ancillary medical products and supplies—available for COVID-19 (or SARS-CoV-2), its variants, and any disease with potential for creating a pandemic. Section 2304 provides $500 million to FDA, available until expended, for a broad set of activities, including for its review of the performance, safety, and effectiveness of vaccines; inspection of vaccine manufacturing facilities; and oversight of the vaccine supply chain. Section 3101 provides $10 billion, available until September 30, 2025, for activities under the Defense Production Act with respect to medical supplies and equipment for the pandemic, including for vaccines and related supplies. Funds can support the purchase, production, and distribution of such supplies. After September 30, 2022, funds can be used to meet critical public health needs with respect to any pathogen that the President has determined has the potential for creating a public health emergency.